First-in-human, phase 1 study of a selective RET inhibitor, LOXO-260, in patients with RET inhibitor refractory, RET-altered cancers Meeting Abstract
| Authors: | Subbiah, V.; Drilon, A.; Bestvina, C.; Garon, E. B.; Wirth, L.; Worden, F.; Piha-Paul, S.; Rotow, J.; Johnson, M.; Kang, H.; Dong, S. M.; Weiss, J.; Pennell, N. A.; Sukrithan, V.; Lombard, A.; Szpurka, A. M.; Li, J.; Manvelyan, M.; Avsar, E.; Brose, M. S. |
| Abstract Title: | First-in-human, phase 1 study of a selective RET inhibitor, LOXO-260, in patients with RET inhibitor refractory, RET-altered cancers |
| Meeting Title: | 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics |
| Journal Title: | European Journal of Cancer |
| Volume: | 211 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Oct 23-25 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-10-01 |
| Start Page: | S41 |
| End Page: | S42 |
| Language: | English |
| ACCESSION: | WOS:001345547300094 |
| DOI: | 10.1016/j.ejca.2024.114622 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 98 (PB086) -- Article number: 114622 -- Source: Wos |
